1 million) during May 1, 1999 and April 30, 2002.![]() | ![]() |
Formats:
|
||||||||||||
Copyright © 2005 Laupland and Church; licensee BioMed Central Ltd. Population-based laboratory surveillance for Giardia sp. and Cryptosporidium sp. infections in a large Canadian health region 1Departments of Critical Care Medicine, Medicine and Pathology & Laboratory Medicine, and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada 2Center for Anti-microbial Resistance, Calgary Health Region, Calgary Laboratory Services and the University of Calgary, Calgary, Canada 3c/o Calgary Laboratory Services, 9-3535 Research Rd. N.W., Calgary, Alberta, T2L 2K8, Canada 4Departments of Pathology & Laboratory Medicine and Medicine, University of Calgary, Calgary, Alberta, Canada 5Calgary Laboratory Services, Calgary, Alberta, Canada Corresponding author.Kevin B Laupland: Kevin.laupland/at/cls.ab.ca; Deirdre L Church: deirdre.church/at/cls.ab.ca Received December 13, 2004; Accepted September 16, 2005. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background Giardia lamblia (intestinalis) and Cryptosporidium parvum are the two most important intestinal parasites infecting North Americans but there is a paucity of active population-based surveillance data from Canada. This study determined the incidence of and demographic risk factors for developing Giardia sp. and Cryptosporidium sp. infections in a general Canadian population. Methods Population-based laboratory surveillance was conducted among all residents of the Calgary Health Region (CHR; population 1 million) during May 1, 1999 and April 30, 2002.Results Giardia sp. infection occurred at a rate of 19.6 per 100,000 populations per year. Although the yearly incidence was stable, a significant seasonal variation was observed with a peak in late summer to early fall. Males were at higher risk for development of this infection as compared to females (21.2 vs. 17.9 per 100,000/yr; relative risk (RR) 1.19; 95% confidence interval (CI), 1.00–1.40, p = 0.047), and there was a significant decrease in risk associated with an increasing age. Cryptosporidium sp. infection occurred at an overall rate of 6.0 per 100,000 populations per year although a large outbreak of Cryptosporidium sp. infections occurred in the second half of the summer of 2001. During August and September of 2001, the incidence of cryptosporidiosis was 55.1 per 100,000 per year as compared to 3.1 per 100,000 per year for the remainder of the surveillance period (p < 0.0001). Cryptosporidiosis was largely a disease of children with an incidence of 17.8 per 100,000 per year occurring among those aged < 20 years of age compared to 1.25 per 100,000 per year for adults ≥ 20 years of age (RR 14.19; 95% CI, 9.77–21.11; p < 0.0001). Conclusion This study provides important information on the occurrence and demographic risk groups for acquisition of giardiasis and cryptosporidiosis in a non-selected Canadian population. Background Giardia lamblia (intestinalis) and Cryptosporidium parvum are the two most important intestinal parasites infecting North Americans [1,2]. Infection with either parasite occurs when cysts are ingested via contaminated hands, food and/or water, or through person to person contact [3,4]. These infections are associated with endemic infection rates in many jurisdictions but they have also caused large outbreaks [5,6]. In Canada, several outbreaks have been reported in recent decades due to Cryptosporidium parvum [7,8] and Giardia lamblia [9]. Population-based surveillance studies conducted in the United States have demonstrated increasing rates for giardiasis between 1992–97 with the highest national rates being amongst children aged 0–5 years, followed closely by persons aged 31–40 years [1,10-12]. In the United States in 1997, giardiasis cases per 100,000 state population ranged from 0.98 to 42.3 with a national average of 9.5 cases per 100,000 population [1]. Similar true population-based rates have not been determined for cryptosporidiosis in North America. Crude estimates from the United States based on monitoring water contamination show an expected Cryptosporidium sp. infection rate of between 1–400 cases per 100,000 population [13]. However, because water-borne transmission is one of the major routes of acquiring infection, it must also be recognized that infection rates for either enteric parasite may vary by geographic location. One study in southern Ontario demonstrated an association between giardiasis and rural areas and this has been corroborated by subsequent GIS spatial scan statistics investigation of clusters of giardiasis in this area [14]. Although a previously study had shown significant associations of giardiasis rates with manure application on agricultural land and livestock density this was not born out using spatial statistics scanning methods [15]. There is a lack of active population-based data on the distribution and determinants of Giardia sp. and Cryptosporidium sp. infections in a Canadian population. The objective of this study was to determine the incidence of and demographic risk factors for acquiring these infections among residents of the Calgary Health Region. Such data is important to establish the burden of disease and assess risk factors for acquiring these infections in a defined geographic locale. Methods Patients The Calgary Health Region (CHR) is a well defined, fully integrated, publicly funded health system that provides virtually all medical and surgical care to the residents of the cities of Calgary and Airdrie and several nearby small towns, villages, and hamlets (2001 population 958,610) [16]. All residents of the CHR who had a positive stool specimen for Giardia sp. or Cryptosporidium sp. during the period from May 1, 1999 and April 30, 2002 were included in this study. Study design A laboratory-based surveillance cohort design was utilized since all stool samples for parasitological testing are routinely submitted to a single regional microbiology laboratory [i.e., Calgary Laboratory Services (CLS)] [17]. CHR physicians order stool tests based on the patient's presenting symptoms typically of a diarrhoeal illness and the presence of other risk factors (i.e., recent travel, exposure to contaminated food or water, immune status etc.). Because there is universal coverage for healthcare services including laboratory tests in Canada, lack of health insurance is not a barrier to stool parasitological testing. All stool samples submitted from community-based or hospital collection sites in the CHR during the study period were identified by use of the Cerner PathNet Classic version 306 (Kansas City, MO) database at Calgary Laboratory Services (CLS) [18]. Patients were deemed to have giardiasis or cryptosporidiosis if an approved diagnostic test was positive for one or both of these infections according to the laboratory procedures outlined below. Once these patients were identified basic demographic information on age and gender was obtained at CLS and data were entered manually into an Excel spreadsheet (Microsoft Corp.). Laboratory procedures All stool parasitological tests were performed by Calgary Laboratory Services (CLS) a large integrated publicly funded medical laboratory company that provides microbiology services from hospitalized and ambulatory patients 24 hours a day, 7 days a week through a centralized facility located in the community. Physicians can order either a Giardia/Cryptosporidium screen or a full stool ova and parasite (O & P) examination on the CLS requisition. Stool parasitological testing proceeded as outlined below depending on the physician's test request. Only a G/C EIA screen was done unless a clinical history was provided on the requisition. All stool specimens that had a stool O & P procedure were initially screened by the G/C EIA procedure. a) Giardia/Cryptosporidium assay A rapid commercially available immunoassay is initially performed when a G/C screen is ordered. A stained slide was also read from all stool samples submitted from children ≤ 14 years of age) in order to screen for the presence of other parasites including Dientamoeba fragilis. Giardia (GSA 65) and Cryptosporidium (CSA) are specific antigens produced by the parasites as they multiply within the host intestinal tract. The ProSpecT® Giardia/Cryptosporidium Microplate (Remel Inc., Lenexa, KS, USA) assay (G/C EIA) is a solid phase immunoassay for the simultaneous detection of both antigens (GSA 65 and CSA). The G/C EIA was performed according to the manufacturer's instructions on unconcentrated formalin-fixed specimens. G/C EIA tests were considered positive if the optical density was 0.050 ≥ at 450 nm. The Meriflor® G/C direct fluorescent antibody (DFA) test (Meridian Bioscience Inc., Cincinnati, OH) was used to confirm the presence of Giardia and/or Cryptosporidium infection. One drop (~10 μl) of the concentrated sediment was thinly spread onto each well of the treated slide and fluorescence light microscopy with a 20X objective was used to read the entire well. b) Stool ova & parasite (stool O & P) method Stool O & P testing (i.e. stained slide and concentrate) were only done on samples where the physician had ordered the test and provided one or more clinical indications for the request as follows: 1) recent travel outside North America or Travel Clinic patient, 2) recent immigration, 3) immune-compromised or specific HIV/AIDS, cancer, transplantation clinic locations, 4) request for worms, tapeworms or Ascaris sp., 5) bloody or bloody stool specimen, 6) Gastroenterologist's patient, and 7) other (Microbiologist-on-call is consulted). Repeated standard wash and centrifugation procedures are used to prepare stool sediment that is stained with Iron Hematoxylin/Kinyoun stain. The entire 20 × 50 mm cover-slipped stained smear is scanned with the 10X objective to look for larger parasitic elements (i.e. ova). The stained slide is then examined for 10 min. per slide using the 50X oil immersion lens and confirmation of any parasitic elements is done under the 100X oil immersion lens. A fecal concentrate is also prepared using a standard ethyl acetate concentration method after preparation of the stained smears. A different technologist reads the concentrate of the same specimen using both the 10X and 40X dry objectives. Analysis Analyses were performed using Stata version 8.0 (Stata Corp., College Station, TX). Differences in proportions in categorical data were compared using Fisher's exact test. Medians with interquartile ranges (IQR) were used to report non-normally distributed continuous variables and were compared using the Wilcoxon Rank-sum test. Incidence rates were calculated using denominator data from the Alberta Health Registry [19]. Only the first sample positive in a given study year was included in the analysis. Category specific risks were calculated and reported as relative risks (RR) with 95% confidence intervals (CI) as previously described [20]. Patients were classified as CHR residents if they had Alberta Health Care numbers and samples were collected at a CHR site or if they were inpatients in a CHR hospital. Results Giardiasis A total of 562 episodes of Giardia sp. infection were identified among 552 patients for an overall incidence of 19.6 per 100,000 populations per year. There was no difference in the yearly incidence of Giardia sp. infection during the three years of the study (p > 0.2). A significant seasonal variation was observed with a peak in late summer to early fall (Figure (Figure1).1
A significant association between age and gender and development of giardiasis was observed (Figure (Figure2).2
Cryptosporidiosis A total of 173 patients were diagnosed with Cryptosporidium sp. infection for an overall incidence of 6.0 per 100,000 populations per year. No patients had repeat episodes of this infection. There was a dramatic difference in the temporal occurrence of Cryptosporidium sp. infection during the three years of the study with a large outbreak occurring in the second half of the summer of 2001 (Figure (Figure3).3
In contrast to giardiasis where adults remained at notably increased risk, cryptosporidiosis was primarily a disease of children and adolescents (Figure (Figure4).4
Males were at slightly higher risk overall for development of cryptosporidiosis as compared to females (6.9 vs. 5.1 per 100,000/yr; RR 1.35; 95% CI, 0.99–1.84, p = 0.053) which was similar to the trend found for giardiasis. No significant association was observed between gender and the presence of the outbreak. Discussion This is the first study that has investigated the occurrence and demographic risk factors for acquiring Giardia sp. and Cryptosporidium sp. infections using a population-based methodology in Canada. Population-based methodologies are widely viewed as optimal designs for establishing the burden of disease because selection bias is minimized since all patients in a defined geographic area are included in surveillance [21-23]. The American Centers for Disease Control (CDC) that is recognized as a leader in infectious disease epidemiology utilizes a very similar methodology for their Active Bacterial Core Surveillance program http://www.cdc.gov/ncidod/dbmd/abcs/methstart.htm. If adequate denominator data is available then incidence rates may be calculated from population-based datasets. The rates we determined in this study should be viewed as the minimum incidence because multiple stool sampling is not a standard practice in our region, and many patients may have had these diseases without having a stool sample submitted for parasitological testing. In addition, certain groups that seek medical attention less frequently may be underrepresented using a population-based laboratory surveillance approach (i.e., shut-in elderly, intravenous drug users, those with mental illness etc.), but these limitations would also be a reality of other approaches. However, even considering these limitations, Giardia and Cryptosporidium result in a significant disease burden in Calgary. We found that infections with Giardia sp. and/or Cryptosporidium sp. were common in our region. Epidemiological analysis of regional stool parasitological testing data over a two-year period demonstrated that these two parasites were the most commonly identified pathogenic enteric protozoa in the Calgary Health Region, which is similar to the rates previously reported in the United States [1,15,24]. Population-based studies in the United States have indicated rates of Giardia sp. infections ranging from 0.98 to 42.3 cases per 100,000 per year with an average of 9.5 cases per 100,000 per year [1]. However, true population based rates for Cryptosporidum sp. based on laboratory surveillance data have been difficult to determine in the United States because most diagnostic laboratories do not routinely perform stool parasitological procedures that would allow detection of this parasite. A recent survey indicates that most laboratories only analyze stool parasitological samples for the presence of Cryptosporidium sp., Cyclspora sp. and Microsporidium sp. on specific request of the physician [25]. Based on laboratory surveillance data from clinical microbiology laboratories, there were a total of 443 cases of cryptosporidiosis reported to the CDC in the United States in 2003 [26] which is much lower than that expected from population-based estimates of infection rates. Estimates for the Cryptosporidium sp. infection rates for the general population (i.e., 1 – 400 cases per 100,000) in the United States have been based on US-wide water monitoring data [27]. The population-based rate of giardiasis and cryptosporidiosis cases in Calgary is similar to the national average rate per 100,000 reported from the United States. However, the rate of Cryptosporidium sp. infections found in our region is well above the proposed acceptable annual risk level of 1 case of infection per 10,000 [13]. Substantially more Cryptosporidium sp. infections were found in our region during the study period. To our knowledge studies conducted to date from Canada have also not been adequately designed to report incidence rates to allow comparison. The results of our study demonstrate that Giardia sp. and Cryptosporidium sp. infections are common with the former occurring at a rate of more than 3 times more frequently. We observed a number of similar and contrasting features among infections due to Giardia and Cryptosporidium sp. Giardia sp. infections occurred more commonly in late summer in our region and may be related to water exposure and the increased use of backcountry recreational areas. On the other hand, there was no apparent yearly seasonal occurrence of sporadic (i.e. non-outbreak related) Cryptosporidium sp. infections in our region (Figure (Figure3).3 Another contrasting feature among these infections was that the age distribution was different. Giardia sp. infections, although most commonly infecting children, occurred across a broad age range (Figure (Figure2).2 Our observation that an outbreak of Cryptosporidium sp. occurred in the third year of the study demonstrates the importance of their detection by conducting population-based studies over extended periods (years). We have previously raised the theoretical potential for bias in population-based studies designed to assess the burden and risk factors for disease if they are conducted in the setting of an outbreak [38]. If this study had only been conducted over a one-year period in 2001 we would have made erroneous inferences on the occurrence and demographic risk factors for endemic disease as evidenced by the dramatically different rate in that year and that outbreak patients were younger. In our opinion it is important that "baseline" or endemic disease be differentiated from outbreak cases in the description of the epidemiology of an infectious disease. We urge authors of other studies to plot cases over time prior to detect outbreaks prior to description. Although our study is novel in Canada and provides important information there are some important limitations that merit discussion. First, this was a laboratory based study and as a result we did not have detailed information on patient clinical variables, treatments, and outcome. Such information may be of interest and use to clinicians. Second, we did not have reliable other data on exposures such as food and water sources, travel, and family exposures. These variables are clearly important in these diseases and have been the focus of other important investigations in Canadian populations [2,12,29,32]. Finally, we did not have actual addresses for all patients and used a definition of CHR residency status that may have resulted in at least some non-CHR residents being classified as residents in our study. As a result we likely overestimated the incidence of these infections and may have made biased assessments of demographic risk factors to at least some degree [21]. Conclusion In conclusion, we present the results of active population-based surveillance for Giardia sp. and Cryptosporidium sp. in a large Canadian region. Giardiasis was endemic, and younger individuals and males were at increased risk. Overall, cryptosporidiosis was much less common than giardiasis, although a large outbreak of cryptosporidiosis occurred during surveillance. These data provide important information on the occurrence and determinants of the two most important intestinal parasitoses in Canada. Competing interests The author(s) declare that they have no competing interests. Authors' contributions DLC performed the laboratory surveillance study at Calgary Laboratory Services and KBL performed the data analysis. Both authors wrote the manuscript. Pre-publication history The pre-publication history for this paper can be accessed here: Acknowledgements The Division of Microbiology, Calgary Laboratory Services performed all of the patient laboratory testing. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||
MMWR CDC Surveill Summ. 2000 Aug 11; 49(7):1-13.
[MMWR CDC Surveill Summ. 2000]Can Med Assoc J. 1979 Feb 3; 120(3):310-2.
[Can Med Assoc J. 1979]Epidemiol Infect. 2004 Oct; 132(5):967-76.
[Epidemiol Infect. 2004]Int J Infect Dis. 2000; 4(2):100-3.
[Int J Infect Dis. 2000]MMWR Surveill Summ. 2004 Oct 22; 53(8):1-22.
[MMWR Surveill Summ. 2004]Int J Health Geogr. 2004 Jun 4; 3(1):11.
[Int J Health Geogr. 2004]Int J Health Geogr. 2003 Aug 11; 2(1):5.
[Int J Health Geogr. 2003]Clin Infect Dis. 2004 Jun 15; 38(12):1736-41.
[Clin Infect Dis. 2004]Pediatrics. 2000 May; 105(5):E60.
[Pediatrics. 2000]Crit Care. 2004 Dec; 8(6):R431-6.
[Crit Care. 2004]Crit Care Med. 2004 Apr; 32(4):992-7.
[Crit Care Med. 2004]MMWR CDC Surveill Summ. 2000 Aug 11; 49(7):1-13.
[MMWR CDC Surveill Summ. 2000]Int J Health Geogr. 2003 Aug 11; 2(1):5.
[Int J Health Geogr. 2003]Bull World Health Organ. 1993; 71(1):1-7.
[Bull World Health Organ. 1993]Clin Infect Dis. 2004 Apr 15; 38 Suppl 3():S198-202.
[Clin Infect Dis. 2004]MMWR Morb Mortal Wkly Rep. 2004 Apr 30; 53(16):338-43.
[MMWR Morb Mortal Wkly Rep. 2004]Am J Trop Med Hyg. 2002 Jun; 66(6):799-803.
[Am J Trop Med Hyg. 2002]Can J Public Health. 1992 Mar-Apr; 83(2):155-8.
[Can J Public Health. 1992]Am J Trop Med Hyg. 1999 Apr; 60(4):578-83.
[Am J Trop Med Hyg. 1999]Infect Dis Clin North Am. 1998 Jun; 12(2):489-501.
[Infect Dis Clin North Am. 1998]J Clin Microbiol. 2004 Jul; 42(7):2944-51.
[J Clin Microbiol. 2004]Am J Trop Med Hyg. 1992 Jul; 47(1):13-9.
[Am J Trop Med Hyg. 1992]Eur J Clin Microbiol Infect Dis. 1996 Jan; 15(1):77-9.
[Eur J Clin Microbiol Infect Dis. 1996]Risk Anal. 2004 Feb; 24(1):209-20.
[Risk Anal. 2004]J Clin Microbiol. 2004 Jul; 42(7):2944-51.
[J Clin Microbiol. 2004]Can Med Assoc J. 1979 Feb 3; 120(3):310-2.
[Can Med Assoc J. 1979]Can J Public Health. 1992 Mar-Apr; 83(2):155-8.
[Can J Public Health. 1992]Am J Trop Med Hyg. 1999 Apr; 60(4):578-83.
[Am J Trop Med Hyg. 1999]Can Med Assoc J. 1978 Aug 12; 119(3):241-2, 247-8.
[Can Med Assoc J. 1978]Crit Care. 2004 Dec; 8(6):R431-6.
[Crit Care. 2004]